Profile: Genetic Technologies Ltd (GENE.O)

Genetic Technologies Limited (GTG), incorporated on January 5, 1987, is a biotechnology company. The Company is engaged the provision of genetic testing services. The Company also conducts out-licensing program in respect of its non-coding deoxyribonucleic acid (DNA) technology and supports a late-stage research project. The Company operates in three segments: Operations, Licensing and Research. The principal geographic segments of the Company include Australia, with the Company’s headquarters being located in Melbourne in the State of Victoria. The Operations segment includes the provision of a range of genetic testing services. The Licensing segment includes the out-licensing of the Group’s non-coding technology. The Research segment includes the undertaking of a range of research and development projects in the field of genetics and related areas. During the fiscal year ended June 30, 2012, the Company launched its new, predictive risk test, BREVAGen. BREVAGen is the clinically validated breast cancer predictive risk assessment tool that combines a woman’s genetic information with clinical data to assist physicians in developing personalized risk management plans.

The Company services markets across four business sectors. The licensing program has granted results to more than 60 commercial and research licenses to various multi-nationals, biotechnology companies, genetic service providers and research institutes. The Company’s business performs a variety of genetic tests on humans and animals, which includes human diagnostics, forensics and animal pedigree tests. The Company’s Australian heritage business consists of the provision of a range of medical, paternity, forensic and animal genetic tests.